{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:44:17Z","timestamp":1790286257139,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","hpbonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["HPB"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.hpb.2026.06.004","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T18:04:09Z","timestamp":1781201049000},"page":"1149-1157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Selective internal radiotherapy vs transarterial chemoembolization for unresectable hepatocellular carcinoma: a systematic review"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5607-8092","authenticated-orcid":false,"given":"Pam E.","family":"van der Meeren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sverre","family":"Beijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0290-0381","authenticated-orcid":false,"given":"Merve","family":"Rousian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay","family":"Pieterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4280-4210","authenticated-orcid":false,"given":"Dave","family":"Sprengers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-2258","authenticated-orcid":false,"given":"Erik","family":"Vegt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Porte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3558-1039","authenticated-orcid":false,"given":"Jan N.M.","family":"Ijzermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roeland F.","family":"de Wilde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hpb.2026.06.004_bib1","series-title":"Hepatocellular carcinoma","author":"Asofa-Agyei","year":"2023"},{"key":"10.1016\/j.hpb.2026.06.004_bib2","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/ijc.33588","article-title":"Cancer statistics for the year 2020: an overview","volume":"149","author":"Ferlay","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1016\/j.hpb.2026.06.004_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.hpb.2026.06.004_bib4","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejca.2021.11.023","article-title":"Global, regional and national burden of primary liver cancer by subtype","volume":"161","author":"Rumgay","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.hpb.2026.06.004_bib5","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-2007-1007122","article-title":"Prognosis of hepatocellular carcinoma: the BCLC staging classification","volume":"19","author":"Llovet","year":"1999","journal-title":"Semin Liv Dis"},{"key":"10.1016\/j.hpb.2026.06.004_bib6","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: Management of hepatocellular carcinoma","volume":"69","author":"Liver","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.hpb.2026.06.004_bib7","series-title":"Hepatic chemoembolization","author":"Young","year":"2023"},{"key":"10.1016\/j.hpb.2026.06.004_bib8","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jhep.2015.02.010","article-title":"Transarterial chemoembolization: modalities, indication, and patient selection","volume":"62","author":"Sieghart","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.hpb.2026.06.004_bib9","doi-asserted-by":"crossref","first-page":"4132","DOI":"10.1007\/s00330-024-11272-8","article-title":"Degradable starch microspheres transarterial chemoembolization (DSM-TACE) in patients with unresectable hepatocellular carcinoma: results from the prospective multicenter observational HepaStar trial","volume":"35","author":"Collettini","year":"2025","journal-title":"Eur Radiol"},{"key":"10.1016\/j.hpb.2026.06.004_bib10","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1002\/hep.29207","article-title":"Prevention and treatment of complications of selective internal radiation therapy: expert guidance and systematic review","volume":"66","author":"Sangro","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.hpb.2026.06.004_bib11","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s12029-020-00502-z","article-title":"SIRT compared with DEB-TACE for hepatocellular carcinoma: a real-world study (the SITAR study)","volume":"52","author":"Hirsch","year":"2021","journal-title":"J Gastrointest Cancer"},{"key":"10.1016\/j.hpb.2026.06.004_bib12","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s00270-014-1012-0","article-title":"Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma","volume":"38","author":"Pitton","year":"2015","journal-title":"Cardiovasc Interv Radiol"},{"key":"10.1016\/j.hpb.2026.06.004_bib13","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1177\/0284185120926474","article-title":"Trans-arterial chemoembolization with degradable starch microspheres (DSM-TACE) versus selective internal radiation therapy (SIRT) in multifocal hepatocellular carcinoma","volume":"62","author":"Auer","year":"2021","journal-title":"Acta Radiol"},{"key":"10.1016\/j.hpb.2026.06.004_bib14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ctrv.2018.11.002","article-title":"Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence","volume":"72","author":"Raoul","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.hpb.2026.06.004_bib15","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.dld.2016.03.031","article-title":"Cost-effectiveness of doxorubicin-eluting beads versus conventional trans-arterial chemo-embolization for hepatocellular carcinoma","volume":"48","author":"Cucchetti","year":"2016","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.hpb.2026.06.004_bib16","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.cgh.2013.04.028","article-title":"Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization","volume":"11","author":"Salem","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.hpb.2026.06.004_bib17","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10585-022-10188-1","article-title":"Portal vein tumor thrombosis in hepatocellular carcinoma: molecular mechanism and therapy","volume":"40","author":"Zhou","year":"2023","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.hpb.2026.06.004_bib18","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1007\/s00261-016-0639-5","article-title":"Hepatic imaging following intra-arterial embolotherapy","volume":"41","author":"Kallini","year":"2016","journal-title":"Abdom Radiol"},{"key":"10.1016\/j.hpb.2026.06.004_bib19","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1102\/1470-7330.2013.0057","article-title":"Yttrium-90 radioembolization of liver tumors: what do the images tell us?","volume":"13","author":"Singh","year":"2014","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.hpb.2026.06.004_bib20","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.hpb.2026.06.004_bib21","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/bjc.2014.199","article-title":"Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma","volume":"111","author":"Golfieri","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.hpb.2026.06.004_bib22","article-title":"Comparison of therapeutic response using RECIST criteria: Y-90 SIR-spheres and TheraSphere treatment of unresectable hepatocellular carcinoma","volume":"54","author":"Zhang","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1016\/j.hpb.2026.06.004_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000267","article-title":"Preoperative\/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages","author":"Gillen","year":"2010","journal-title":"PLoS Med"},{"key":"10.1016\/j.hpb.2026.06.004_bib25","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jhep.2016.01.012","article-title":"Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial","volume":"64","author":"Lencioni","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.hpb.2026.06.004_bib26","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1053\/j.gastro.2016.08.029","article-title":"Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma","volume":"151","author":"Salem","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.hpb.2026.06.004_bib27","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S2468-1253(17)30156-5","article-title":"Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial","volume":"2","author":"Meyer","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.hpb.2026.06.004_bib28","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","article-title":"Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial","volume":"18","author":"Vilgrain","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hpb.2026.06.004_bib29","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1200\/JCO.2017.76.0892","article-title":"SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma","volume":"36","author":"Chow","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hpb.2026.06.004_bib30","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S2468-1253(17)30290-X","article-title":"Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study","volume":"3","author":"Kudo","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.hpb.2026.06.004_bib31","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1148\/radiol.211806","article-title":"(90)Y radioembolization versus drug-eluting bead chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phase II randomized controlled trial","volume":"303","author":"Dhondt","year":"2022","journal-title":"Radiology"},{"key":"10.1016\/j.hpb.2026.06.004_bib32","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1002\/cncr.34965","article-title":"Proton beam radiotherapy versus transarterial chemoembolization for hepatocellular carcinoma: results of a randomized clinical trial","volume":"129","author":"Bush","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.hpb.2026.06.004_bib33","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ijrobp.2023.03.064","article-title":"Transarterial chemoembolization with drug-eluting beads versus stereotactic body radiation therapy for hepatocellular carcinoma: outcomes from a multicenter, randomized, phase 2 trial (the TRENDY trial)","volume":"117","author":"Mendez","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.hpb.2026.06.004_bib34","series-title":"Common terminology criteria for adverse events (CTCAE) v4.0","year":"2009"},{"key":"10.1016\/j.hpb.2026.06.004_bib35","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.hpb.2026.06.004_bib36","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jhep.2017.12.026","article-title":"Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion","volume":"68","author":"Spreafico","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.hpb.2026.06.004_bib37","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ctrv.2010.07.006","article-title":"Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization","volume":"37","author":"Raoul","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.hpb.2026.06.004_bib38","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1111\/liv.12818","article-title":"Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study","volume":"35","author":"Park","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.hpb.2026.06.004_bib39","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ejrad.2017.05.022","article-title":"Comparative study of post-transplant outcomes in hepatocellular carcinoma patients treated with chemoembolization or radioembolization","volume":"93","author":"Gabr","year":"2017","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.hpb.2026.06.004_bib40","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/hep.31819","article-title":"Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study","volume":"74","author":"Salem","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.hpb.2026.06.004_bib41","doi-asserted-by":"crossref","first-page":"449","DOI":"10.7861\/clinmedicine.17-5-449","article-title":"Selective internal radiation therapy for liver tumours","volume":"17","author":"Sundram","year":"2017","journal-title":"Clin Med"},{"key":"10.1016\/j.hpb.2026.06.004_bib42","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3348\/jksr.2025.0032","article-title":"Radioembolization: technical tips and Follow-Up imaging","volume":"86","author":"Kim","year":"2025","journal-title":"J Korean Soc Radiol"},{"key":"10.1016\/j.hpb.2026.06.004_bib43","first-page":"1167=74","article-title":"Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: longitudinal prospective study","volume":"30","author":"Xing","year":"2015","journal-title":"J Gastroenteral Hepatol"},{"key":"10.1016\/j.hpb.2026.06.004_bib44","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00259-015-3157-8","article-title":"Clinical impact of (99m)Tc-MAA SPECT\/CT-based dosimetry in the radioembolization of liver malignancies with (90)Y-loaded microspheres","volume":"43","author":"Garin","year":"2016","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.hpb.2026.06.004_bib45","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2967\/jnumed.114.145177","article-title":"Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis","volume":"56","author":"Garin","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/j.hpb.2026.06.004_bib46","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.ejmp.2014.05.004","article-title":"Liver selective internal radiation therapy with (90)Y resin microspheres: comparison between pre-treatment activity calculation methods","volume":"30","author":"Bernardini","year":"2014","journal-title":"Phys Med"},{"key":"10.1016\/j.hpb.2026.06.004_bib47","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.hpb.2026.06.004_bib48","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL clinical practice guidelines on the management of hepatocellular carcinoma","volume":"82","author":"Sangro","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.hpb.2026.06.004_bib49","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1136\/flgastro-2022-102137","article-title":"Selective internal radiation therapy (SIRT) for hepatocellular carcinoma (HCC): informing clinical practice for multidisciplinary teams in England","volume":"14","author":"Reeves","year":"2023","journal-title":"Frontline Gastroenterol"},{"key":"10.1016\/j.hpb.2026.06.004_bib50","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1007\/s00270-022-03228-6","article-title":"SIRT in 2025","volume":"45","author":"Ponziani","year":"2022","journal-title":"Cardiovasc Interv Radiol"}],"container-title":["HPB"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1365182X2600660X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1365182X2600660X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:09:21Z","timestamp":1788966561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1365182X2600660X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":49,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1365182X2600660X"],"URL":"https:\/\/doi.org\/10.1016\/j.hpb.2026.06.004","relation":{},"ISSN":["1365-182X"],"issn-type":[{"value":"1365-182X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selective internal radiotherapy vs transarterial chemoembolization for unresectable hepatocellular carcinoma: a systematic review","name":"articletitle","label":"Article Title"},{"value":"HPB","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hpb.2026.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of International Hepato-Pancreato-Biliary Association Inc.","name":"copyright","label":"Copyright"}]}}